Patents

U.S. FTC will not file objections to settlement of patent dispute over venlafaxine

Published in Medical Letter on the CDC and FDA, January 8th, 2006

The U.S. Federal Trade Commission (FTC) has notified Wyeth (WYE) that it will not file an objection with the United States District Court for the District of New Jersey to the proposed settlement of the patent litigation between Wyeth and Teva Pharmaceutical Industries, Ltd., (TEVA).

The litigation concerns Teva's application to market an extended-release venlafaxine capsule product.

Wyeth markets extended-release venlafaxine under the trade name Effexor XR.

Wyeth and Teva will now file motions with the court requesting that the court approve the settlement and enter related orders.

This article was prepared by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry